← FDA DRUG APPROVALS

FDA ANDA · ANDA077794

OXCARBAZEPINE

Sponsor: SUN PHARM INDS

APPLICATION
ANDA077794
TYPE
ANDA
ORIGINAL APPROVAL
2007-10-09
LATEST ACTION
2020-08-26
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

OXCARBAZEPINEPrescription
OXCARBAZEPINE 300MG · TABLET · ORAL
OXCARBAZEPINEPrescription
OXCARBAZEPINE 600MG · TABLET · ORAL
OXCARBAZEPINEPrescription
OXCARBAZEPINE 150MG · TABLET · ORAL

Approval history

2020-08-26Labeling · Supplement 19 · standardAP
2020-08-26Labeling · Supplement 15 · standardAP
2020-08-26Labeling · Supplement 13 · standardAP
2016-06-23Labeling · Supplement 11 · standardAP
2015-01-20Labeling · Supplement 7 · standardAP
2015-01-20Labeling · Supplement 8 · standardAP
2010-06-29Labeling · Supplement 4AP
2007-10-09OriginalLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →